Cancer chemotherapy and cardiovascular risks: Is capecitabine-induced hypertriglyceridemia a rare adverse effect?

Cardiology

Volumn 116, Issue 1, 2010, Pages 42-44

  Seminara, Patrizia ^a   Losanno, Tania ^a   Emiliani, Alessandra ^a   Manna, Gaia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Capecitabine; Cardiovascular risks; Chemotherapy; Hypertriglyceridemia

Indexed keywords

ATORVASTATIN; BEVACIZUMAB; CAPECITABINE; LIPID; NAVELBINE; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; TEMSIROLIMUS; TRIACYLGLYCEROL;

ADVANCED CANCER; ANEMIA; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; HEAD AND NECK CARCINOMA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; METABOLIC DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CARCINOMA; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 77951601165     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313517     Document Type: Article

References (16)

1. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capacitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
2. van Custen E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL: Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190-1197.
3. Okines A, Chau I, Cunningham D: Capecitabine in gastric cancer. Drugs Today (Barc) 2008; 44: 629-640.
4. Package insert: Xeloda (Capecitabine). Nutley, Roche Pharmaceuticals, 2005.
5. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guter N: Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 2006; 40: 328-331.
6. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP: Capecitabine-induced hypertriglyceridemia: a report of two cases. Anticancer Research 2006; 26: 2249-2252.
7. Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Delicanstantinos G: Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects. Anticancer Res 2007; 27: 1653-1656.
8. Bar-Sela G, Haim N: Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemother Pharmacol 2009; 63: 779-782.
9. Yancik R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi WK, Edwards BK: Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol1996; 6: 399-412.
10. Wun T, White RH: Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009; 1: 63-74.
11. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP: Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009; 35: 175-184.
12. Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL: Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115: 4442-4449.
13. Gresset SM, Shah SR: Intricacies of Bevacizumab- induced toxicities and their management. Ann Pharmacol 2009; 43: 490-501.
14. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP: Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25: 3958-3964.
15. Franchi F, Grassi P, Ferro D, Pigliucci G, De Chicchis M, Castigliani G, Pastore C, Seminara P: Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. Eur J Cancer Care 2007; 16: 258-262.
16. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI: Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 1633-1641.